Compare BIO-TECHNE Corp (TECH) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Materials Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Materials Select Sector SPDR Fund trades at $50.12. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Materials Select Sector SPDR Fund pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| TECH | XLB | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $53.62 |
52-Week Low | $43.31 | $42.23 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
XLB trades at $50.03, down 0.99% with a bearish technical signal from moving averages. The materials ETF faces mixed sentiment as recent news highlights sector opportunities from infrastructure trends and geopolitical supply chain shifts, though some analysts caution on valuation after recent gains. Support levels cluster around $49-50 while resistance sits at $51.
Outlook remains cautious with technical weakness offset by structural demand drivers. Key risks include geopolitical sensitivity and cyclical pricing pressure, while potential exists from manufacturing expansion and critical minerals focus. The neutral oscillator readings suggest limited near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
